Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Post by Northforce13on Oct 09, 2022 12:43am
1195 Views
Post# 35014541

M&A Imminent

M&A ImminentThere was an overwhelming amount of talk and indications on the last conference call that a M&A deal was imminent, if not already in the works.  If I recall, they changed CFOs, but kept the old CFO for the time being so that he could work on M&A.  I interpreted this as a deal, or more than one, was in the works and there was a lot of work being done.

Another "possible" indication is that, thus far, CPH has not bought back any shares under the NCIB in October thus far.  Sometimes they would skip a day or two, but never more.  This is abnormal, and indicates to me a good probability that they have a deal that is VERY imminent.  

SP seems sticky around 3.20-3.25 range of late.  

Holding patiently.

GLTA
<< Previous
Bullboard Posts
Next >>